Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q3 FY26 › vs Q3 FY25
Arrowhead Pharmaceuticals (ARWR) Q3 FY26 vs Q3 FY25 (year over year)
Arrowhead Pharmaceuticals's revenue rose $47.5M (+171%) from $27.8M in Q3 FY25 to $75.3M in Q3 FY26.
Arrowhead Pharmaceuticals, Q3 FY26: revenue $75.3M (+171% year over year), operating margin -226.0%, net loss $179M, operating cash flow −$177M. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $75.3M | $27.8M | $47.5M | +171% |
| Net loss | $179M | $179M | $264K | +0.1% |
| Costs & expenses | $254M | $207M | $47.3M | +23% |
| Operating costs | $245M | $193M | $52.0M | +27% |
| Interest & other, net | $8.8M | $13.5M | −$4.7M | -35% |
| Income tax | $11K | −$437K | $448K | — |
| Research & development | $198M | $162M | $35.9M | +22% |
| SG&A | $47.1M | $30.9M | $16.2M | +52% |
| Operating cash sources | $199M | $174M | $25.0M | +14% |
| Depreciation & amortization | $6.2M | $5.8M | $400K | +7% |
| Share-based compensation | $14.9M | $13.0M | $1.8M | +14% |
| Cash used in operations | $177M | $155M | $22.7M | +15% |
| Net loss absorbed | $179M | $179M | $264K | +0.1% |
| Working capital & other | $19.6M | −$5.1M | $24.7M | — |
Questions
How much did Arrowhead Pharmaceuticals's revenue grow year over year in Q3 FY26?
Arrowhead Pharmaceuticals's revenue rose $47.5M (+171%) from $27.8M in Q3 FY25 to $75.3M in Q3 FY26.